Pharmaceuticals. 2024 Aug 5. doi: 10.3390/ph17081033.
B.Dhaini, P.Arnoux, J.Daouk, et al.
Original Research
GBM trial of AGuIX nanoparticles with radiotherapy and temozolomide in the treatment of newly diagnosed Glioblastoma: Phase 1b outcomes and MRI-based biodistribution
Clinical and Translational Radiation Oncology. 2024 Jul 31. doi: 10.1016/j.ctro.2024.100833.
J.Biau, X.Durando, F.Boux, et al.
Gadolinium-based nanoparticles AGuIX and their combination with ionizing radiation trigger AMPK-dependent proinflammatory reprogramming of tumor-associated macrophages
Immunologie. 2024 Jan 15. doi: 10.1101/2024.01.12.575217.
Z.Muradova, D.Tannous, A.Mostefa-Kara, et al.
AGuIX nanoparticle-nanobody bioconjugates to target immune checkpoint receptors
Nanoscale. 2024 Feb 1;16(5):2347-2360. doi: 10.1039/d3nr04777f.
L.Carmès, G.Bort, F.Lux, et al.
Biological modeling of gadolinium-based nanoparticles radio-enhancement for kilovoltage photons: a Monte Carlo study
Cancer Nanotechnology. 2023 May 2. doi: 10.1186/s12645-023-00202-w
J.Wu, X.Xu, Y.Liang, et al.
Gadolinium-Based Nanoparticles Sensitize Ovarian Peritoneal Carcinomatosis to Targeted Radionuclide Therapy
J Nucl Med. 2023 Dec 1;64(12):1956-1964. doi: 10.2967/jnumed.123.265418.
C.Diaz Garcia-Prada, L.Carmès, S.Atis, et al.
Tuning ultrasmall theranostic nanoparticles for MRI contrast and radiation dose amplification
Theranostics. 2023 Aug 21;13(14):4711-4729. doi: 10.7150/thno.85663. eCollection 2023.
N.Brown, P.Rocchi, L.Carmès, et al.